2023
Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia
Ramakrishnan A, Datta I, Panja S, Patel H, Liu Y, Craige M, Chu C, Jean-Marie G, Oladoja A, Kim I, Mitrofanova A. Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Frontiers In Oncology 2023, 13: 1222168. PMID: 37746266, PMCID: PMC10512286, DOI: 10.3389/fonc.2023.1222168.Peer-Reviewed Original ResearchAcute myeloid leukemiaProstate cancerYears of ageAML progressionCancer progressionMyeloid leukemiaStratified survival analysisBiological agingHigh Gleason scoreCox proportional hazardsMarker of progressionProstate cancer progressionPersonalized therapeutic managementMultiple cancer typesAML incidenceOverall survivalPrognostic factorsGleason scoreTherapeutic managementPatient cohortRisk scorePatientsCancer aggressivenessChronological agingProportional hazards
2022
Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis
Harrington C, Krishnan S, Mack CL, Cravedi P, Assis DN, Levitsky J. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. Hepatology 2022, 76: 1862-1879. PMID: 35611859, PMCID: PMC9796683, DOI: 10.1002/hep.32591.Peer-Reviewed Original ResearchConceptsAutoimmune hepatitisNormal serum transaminasesPediatric autoimmune hepatitisFirst-line treatmentAcute liver failureImmune cell phenotypesPredictors of responseHigh clinical valueNovel candidate biomarkersPersonalized therapeutic managementSystemic corticosteroidsCurrent regimensMedication titrationHistological activityMost patientsClinical courseLiver failureLiver injurySerum transaminasesMedication dosingTherapeutic managementUnclear etiologyHepatic fibrosisClinical valueElevated risk
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply